All News

RheumNow Podcast square

Mono- and Oligo- are Different (8.18.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

Read Article
RheumNow Podcast square

English for the Biologically-Challenged (8.4.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

Read Article
RheumNow Podcast square

Anti-Drug Antibodies with Biologics (7.14.2023)

Jack Cush, MD

Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!

Read Article
artangiogca.jpg

GCA and the Risk of Cerebrovascular Ischemic Events

Jack Cush, MD

Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital. 

Read Article
ild.jpg

Scary Outcomes with Systemic Sclerosis Sine Scleroderma

Jack Cush, MD

The hallmark of systemic sclerosis is scleroderma, but less than 10% of SSc patients have sine scleroderma (ssSSc). A EUSTAR database review compared the manifestations and outcomes of ssSSC to limited cutaneous SSc and diffuse cutaneous SSc.

Read Article
ANCA.jpg

Predictors of Cardiovascular Events in ANCA-Associated Vasculitis

Jack Cush, MD

A large, retrospective, multinational study of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) shows they may be at risk for cardiovascular events (CVEs).

Read Article
AE, Side effects

Check SSc-ILD Patients on Nintedinib for Malnutrition

MedPage Today

During nintedanib treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD), clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.

Read Article
Study of 3082 pts w/ muscle disease; 14 had adult IIM w/ myocarditis. Mean: 54 yrs, 71% black, Antisynthetase syndrome in 64% (Jo1=4, PL12=3); 79%) w/ active myositis, 93% hosp); 5 yr myocarditis survival 53% (6 died; all w/ LVEF < 40%) https://t.co/HChGMU2nBv https://t.co/36weNDoV97

Links:

Dr. John Cush RheumNow ( View Tweet)
Hong Kong study shows Very low dose prednisolone (<5 mg/d) doesn't confer excessive CV risk. 2 233 RA pts (105 826 Pt-years FUV; mean duration 8.7 yrs) - 7% developed MACE. MACE risk incr 7% per month in those taking ≥5 mg pred. https://t.co/lcehOgaqCQ https://t.co/AhWGnUuYcc

Links:

Dr. John Cush RheumNow ( View Tweet)
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include: - rapidly progressive interstitial lung disease - anti-Ro52 antibody - age > 57 years (based on study of 126 MDA-5+ DM pts) https://t.co/VCyLhStFgX https://t.co/y3CyzOlwDt

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of Veterans, Medicare, Medicaid RA pts (73070) pts, matched 1:10 w/ non-RA (639268) looked ataortic valve risk; RA pts have incr risk incident AS (adj HR 1.48), aortic valve surgery (aHR 1.34) & AS-related death (aHR 1.26). AS incidence=3.97/1000PYs https://t.co/rvA59hn6FE https://t.co/IS9jjuhYWv

Links:

Dr. John Cush RheumNow ( View Tweet)
Estimated 795 000 Americans are misdiagnosed annually (371,000 pts die; 424,000 permanently disabled). Just 15 diseases account for about half of all serious harms & top 5 (Stroke, Sepsis, Pneumonia, VTE, Lung CA) account for 39% https://t.co/3pvgGLLHbs https://t.co/94ij9txIyK

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of >19K RA pts in National Databank showed that Opioids vs NSAID use had similar MACE risk(20.6 vs 18.9/1000 PY), but opioids had higher mortality (13.5 vs 10.8/1000 PY; HR1.33) & VTE risk(HR=1.41). Opioids are not safer than NSAIDs https://t.co/J56BqYMKM1 https://t.co/xiz4GGUnJC

Links:

Dr. John Cush RheumNow ( View Tweet)
GCA and the Risk of Cerebrovascular Ischemic Events Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital. https://t.co/MAjgWg71vK https://t.co/UhMtiWf7gh

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read review of clinical trials in CTD-ILD, specifically looking at: - Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes - Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq

Links:

Dr. John Cush RheumNow ( View Tweet)
Check SSc-ILD Patients on Nintedinib for Malnutrition During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested. https://t.co/TmN71qSCb2 https://t.co/TVU2qcPdZE

Links:

Dr. John Cush RheumNow ( View Tweet)
Predictors of Cardiovascular Events in ANCA-Associated Vasculitis A large, retrospective, multinational study of patients with ANCA-AAV shows they may be at risk for CVEs. https://t.co/k9XPolEXKc https://t.co/0nxai3Eqe2

Links:

Dr. John Cush RheumNow ( View Tweet)
Check SSc-ILD Patients on Nintedinib for Malnutrition During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested. https://t.co/5Q3xCwLvPa https://t.co/mGD3DCYZR0

Links:

Dr. John Cush RheumNow ( View Tweet)
JAKi in Rheumatoid Arthritis: Cancer and Cardiovascular Risks Dr. Antoni Chan discusses abstracts OP0132, POS0831, and OP0133 presented at EULAR 2023 in Milan, Italy. https://t.co/ApLaPf7uKP https://t.co/nbZgwIlHyb

Links:

Dr. John Cush RheumNow ( View Tweet)
Among 247.3 million US adults. 10.0% (20.3 million) had CVD & 56% were at risk for CVD. Yet only 3.6 million CVD (18%) & 34.5 million at risk for CVD (26%) used wearable devices (compared to 29% in US adults, but less than half wear every day. https://t.co/04xqtkw61x https://t.co/ETTjamvHi2

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×